Rosemont is delighted to announce the appointment of Sasa Leskovsek as Chief Scientific Officer. Sasa completes the Executive Leadership Team following other recent announcements of Chief Commercial and Financial Officers in place.
With more than 20 years' experience in pharmaceutical and R&D organisations; Sasa has strong leadership experience and has led global multi-site teams composing of R&D, regulatory affairs, medical affairs, pharmacovigilance, portfolio, project management and clinical development. Sasa has a PhD from the University of Ljubljana and a MBA from IEDC Bled School of Management. He has worked as an advisor for leading investment funds, multi-national professional service firms and pharma/biotech companies including Ethypharm, Sanofi and Polpharma.
Howard Taylor, Chief Executive Officer, commented “Our mission is to be a rapid developer, reliable manufacturer and global supplier of novel-delivery, patient-focused medicines. Sasa is already playing a significant part in our company’s growth on an international scale. Several of our key functions and departments will thrive under Sasa’s strong and effective leadership. This in turn will drive the expansion of our product offering to a greater number and variety of patients.”